| Literature DB >> 34825343 |
Maria Fernanda Desentis-Desentis1.
Abstract
In both type 1 diabetes (T1D) and type 2 diabetes (T2D), there is a substantial β-cell mass loss. Residual β-cell mass is susceptible to cellular damage because of specific pancreatic β-cell characteristics. β cells have a low proliferation rate, being in human adults almost zero and a low antioxidant system that makes β cells susceptible to oxidative stress and increases their vulnerability to cell destruction. Different strategies have been addressed to preserve pancreatic β-cell residual mass and function in patients with diabetes. However, the effect of many compounds proposed in rodent models to trigger β-cell replication has different results in human β cells. In this review, scientific evidence of β-cell of two major regenerative approaches has been gathered. Regeneration proceedings for pancreatic β cells are promising and could improve β-cell proliferation capacity and contribute to the conservation of mature β-cell phenotypic characteristics. This evidence supports the notion that regenerative medicine could be a helpful strategy to yield amelioration of T1D and T2D pathogenesis.Entities:
Keywords: Dedifferentiation; Diabetes.; Proliferation; Redifferentiation; Regenerative; β-cell mass
Mesh:
Substances:
Year: 2021 PMID: 34825343 DOI: 10.1007/s12020-021-02941-5
Source DB: PubMed Journal: Endocrine ISSN: 1355-008X Impact factor: 3.633